Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403 | 0.89 | — | — | |
| SCHEMBL30800905 | 0.89 | GAA (0.65) | GAAMGAMSIMGAM2ALDH1A1 | |
| Water SCHEMBL555135 | 0.86 | — | — | |
| SCHEMBL16698948 | 0.86 | — | — | |
| Ammonia Solution, Strong SCHEMBL3152412 | 0.86 | — | — | |
| Alcohol SCHEMBL9306984 | 0.86 | GAA (0.62) | GAAMGAMSIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2655390 | 0.86 | — | — | |
| Water SCHEMBL2542900 | 0.86 | GAA (0.62) | GAAMGAMSIMGAM2ALDH1A1 | |
| Acetone SCHEMBL8627214 | 0.84 | GAA (0.59) | GAAMGAMSIMGAM2ALDH1A1 | |
| Cyclohexane SCHEMBL509461 | 0.82 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1771440-A4 | GENERIC PROBES FOR THE DETECTION OF PHOSPHORYLATED SEQUENCES | AMGEN INC (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1771440-A1 | GENERIC PROBES FOR THE DETECTION OF PHOSPHORYLATED SEQUENCES | Amgen, Inc (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1701954-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20060089414-A1 | Generic probes for the detection of phosphorylated sequences | AMGEN INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2006014645-A1 | GENERIC PROBES FOR THE DETECTION OF PHOSPHORYLATED SEQUENCES | AMGEN INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2005066165-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | CXCR4, CXCR1, CXCL12 | GAA 3655/4885MGAM 4390/4885SI 1618/4885 |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | GAA 2654/4885MGAM 4511/4885SI 3506/4885 |
| US-20060089414-A1 | Generic probes for the detection of phosphorylated sequences | ACP1, PTPRG, PTPRF | GAA 749/4885MGAM 1171/4885SI 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.